Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

With a test currently under FDA review, Inflammatix commences a 600 patient-strong clinical trial in emergency departments.

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

TORONTO — Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...